The opening salvo of anti-complement therapy against COVID-19

The COVID-19 pandemic remains unrelenting as the autumn of 2020 approaches. Despite many clinical trials underway to find effective treatments for COVID-19, few studies have yielded positive results. Increasing evidence shows diffuse activation of the complement pathway in severe COVID-19 infections, from increased serum levels to widespread deposition in autopsy specimens.1–4 Initial case…

Read the full article here

Related Articles